Loading...
Docoh

Ionis Pharmaceuticals (IONS)

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.

Company profile

Ticker
IONS
Exchange
CEO
Brett Monia
Employees
Incorporated
Location
Fiscal year end
Former names
ISIS PHARMACEUTICALS INC
SEC CIK
Subsidiaries
Akcea Therapeutics, Inc. • Akcea Therapeutics Canada Inc. • Akcea Therapeutics France SAS • Akcea Therapeutics Germany GmbH • Akcea Therapeutics UK Limited • Akcea Securities Corporation. • Akcea Therapeutics Ireland Limited • Isis USA Limited • Osprey Therapeutics, Inc. • PerIsis I Development Corporation ...
IRS number
330336973

IONS stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Aug 22
19 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 521.92M 521.92M 521.92M 521.92M 521.92M 521.92M
Cash burn (monthly) 6.87M 3.6M 34.29M 2.32M 6.03M (no burn)
Cash used (since last report) 11.54M 6.05M 57.67M 3.91M 10.14M n/a
Cash remaining 510.37M 515.86M 464.25M 518.01M 511.77M n/a
Runway (months of cash) 74.3 143.3 13.5 223.0 84.8 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 22 Eric Swayze Common Stock Sell Dispose S No Yes 45.2 1 45.2 20,352
15 Jul 22 Berthelsen Spencer R Common Stock Option exercise Acquire M No No 0 2,665 0 128,897
15 Jul 22 Berthelsen Spencer R Common Stock Option exercise Acquire M No No 0 5,333 0 126,232
15 Jul 22 Berthelsen Spencer R RSU Common Stock Option exercise Dispose M No No 0 2,665 0 7,110
15 Jul 22 Berthelsen Spencer R RSU Common Stock Option exercise Dispose M No No 0 5,333 0 9,775
15 Jul 22 Hayden Michael R Common Stock Option exercise Acquire M No No 0 1,777 0 21,332
15 Jul 22 Hayden Michael R Common Stock Option exercise Acquire M No No 0 5,333 0 19,555
15 Jul 22 Hayden Michael R RSU Common Stock Option exercise Dispose M No No 0 1,777 0 8,887
15 Jul 22 Hayden Michael R RSU Common Stock Option exercise Dispose M No No 0 5,333 0 10,664
15 Jul 22 Allene M. Diaz Common Stock Option exercise Acquire M No No 0 8,000 0 8,000
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?
Risks
  • Our business could be materially adversely affected by the effects of health epidemics. To date, we believe the impacts of the recent COVID-19 pandemic on our business are limited and manageable.
  • We have limited experience as a company in commercializing medicines and we will have to invest significant resources to develop these capabilities. If we are unable to establish effective marketing, sales, market access, distribution, and related functions, or enter into agreements with third parties to commercialize our medicines, we may not be able to generate revenue from our medicines.
  • If the market does not accept our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, we are not likely to generate substantial revenues or become consistently profitable.
  • If we or our partners fail to compete effectively, our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, will not generate significant revenues.
  • Our medicines could be subject to regulatory limitations following approval.
  • We depend on our collaboration with AstraZeneca for the joint development and commercialization of eplontersen.
  • We are relying on third parties to market, sell and distribute TEGSEDI and WAYLIVRA.
  • If government or other third-party payers fail to provide adequate coverage and payment rates for our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, our revenue will be limited.
  • If we cannot manufacture our medicines or contract with a third party to manufacture our medicines at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.*
  • If we or our partners fail to obtain regulatory approval for our medicines and additional approvals for SPINRAZA, TEGSEDI and WAYLIVRA, we or our partners cannot sell them in the applicable markets.
  • We may not be able to benefit from orphan drug designation for our medicines.
  • If the results of clinical testing indicate that any of our medicines are not suitable for commercial use, we may need to abandon one or more of our drug development programs.
  • Even if our medicines are successful in preclinical and human clinical studies, the medicines may not be successful in late-stage clinical studies.
  • We depend on third parties to conduct our clinical studies for our medicines and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.*
  • Since corporate partnering is a significant part of our strategy to fund the advancement and commercialization of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our drug development programs.
  • Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development and commercial programs.
  • If we do not progress in our programs as anticipated, the price of our securities could decrease.
  • We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.
  • Intellectual property litigation could be expensive and prevent us from pursuing our programs.
  • If our management transition is not successful our business could suffer.
  • The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.
  • Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.
  • Our future taxable income could be impacted by changes in tax laws, regulations and treaties.
  • We could be subject to additional tax liabilities.
  • If the price of our securities continues to be highly volatile, this could make it harder to liquidate your investment and could increase your risk of suffering a loss.*
  • Provisions in our certificate of incorporation, convertible notes documents, call spread hedge transaction documents and Delaware law may prevent stockholders from receiving a premium for their shares.
  • Future sales of our common stock in the public market could adversely affect the trading price of our securities.
  • We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.
  • We are dependent on information technology systems, infrastructure and data, which exposes us to data security risks.*
  • Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
  • Our business may be adversely affected by climate change, extreme weather events, earthquakes, pandemics, war, civil or political unrest, terrorism or other catastrophic events.
  • Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.
  • Negative conditions in the global credit markets and financial services and other industries may adversely affect our business.*
  • The impact on us of the vote by the United Kingdom to leave the European Union cannot be predicted.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman V good
New words: abetting, accrual, AGT, AMD, attaching, bepirovirsen, burden, carrier, cerebrospinal, chronic, Cohen, Compromise, degeneration, dry, Factor, Food, HBV, hearing, HTT, huntingtin, iDMC, IgAN, immunoglobulin, insignificantly, Liver, macular, NDA, nephropathy, Notice, PDUFA, pediatric, Pendency, portfolio, redeploying, Release, residual, Robert, stabilized, statistically, suggested, toxicology, user, wrongdoing, XI, younger
Removed: aro, ATL, Atlantic, Bicycle, BV, Dynacure, Empirico, Flamingo, launched, ProQR, ruling, SAS, Science, Sense, shifted, TTR